LunarCrush LLM | creator/twitter::1721917839534170112/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@3in5saved](/creator/twitter/3in5saved)
"I think Amgen took their shot underestimated InflaRx biotech capabilities now a race to hopefully break even. Doubt they would sink more billions into this space. When AstraZeneca bought Alexion back in 2021 for $39b it came with Alexion blockbusters Soliris (eculizumab) and Ultomiris (ravulizumab) anti-C5 biotech of preclinical work that started way back in the 1990s. Thats a lot of time to be thinking about indications applicable to C5a-C5aR1 signaling. Over those decades of R&D it would seem likely that they also explored targeting the axis components but for whatever reason never got"  
[X Link](https://x.com/3in5saved/status/1980967928997593164) [@3in5saved](/creator/x/3in5saved) 2025-10-22T12:02Z XXX followers, XX engagements


"@StreetCred2017 @YBoyrov @Bionavgator @BARDA $AMGN too at $162b. They liked a C5aR1 inhibitor (avacopan) enough to bid $3.7b for ChemoCentryx when the drug got approval to treat neutrophilic disease AAV. Seems C5aR1 inhibitor INF904 is quite the bargain. For now"  
[X Link](https://x.com/3in5saved/status/1980754175236374617) [@3in5saved](/creator/x/3in5saved) 2025-10-21T21:52Z XXX followers, XXX engagements


"Party E: $AZN AstraZeneca ($258b mcap) I uploaded all the bidding details to both GPT and Grok requesting best guesses for each party. Then I asked Grok to review GPTs guesses against its guesses and then arrive at a final table; same for GPT of Groks guesses. Here are the final tables GPT then Grok with the following comments: GPT: Groks framework is quite credible especially for Party E = AstraZeneca and Party B = Roche which align with both transaction logic and historical behaviors. The main divergence is Party A where the Novartis link is just too strong to ignore and Party D where CSL"  
[X Link](https://x.com/3in5saved/status/1980847537641701870) [@3in5saved](/creator/x/3in5saved) 2025-10-22T04:03Z XXX followers, XXX engagements


"@BioTechTraderSD What of the fundamentals though as to truth. What do you think about the role of neutrophils in disease severity of HS and the associated significance of C5a-C5aR1 signaling"  
[X Link](https://x.com/3in5saved/status/1981021853247283405) [@3in5saved](/creator/x/3in5saved) 2025-10-22T15:36Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@3in5saved "I think Amgen took their shot underestimated InflaRx biotech capabilities now a race to hopefully break even. Doubt they would sink more billions into this space. When AstraZeneca bought Alexion back in 2021 for $39b it came with Alexion blockbusters Soliris (eculizumab) and Ultomiris (ravulizumab) anti-C5 biotech of preclinical work that started way back in the 1990s. Thats a lot of time to be thinking about indications applicable to C5a-C5aR1 signaling. Over those decades of R&D it would seem likely that they also explored targeting the axis components but for whatever reason never got"
X Link @3in5saved 2025-10-22T12:02Z XXX followers, XX engagements

"@StreetCred2017 @YBoyrov @Bionavgator @BARDA $AMGN too at $162b. They liked a C5aR1 inhibitor (avacopan) enough to bid $3.7b for ChemoCentryx when the drug got approval to treat neutrophilic disease AAV. Seems C5aR1 inhibitor INF904 is quite the bargain. For now"
X Link @3in5saved 2025-10-21T21:52Z XXX followers, XXX engagements

"Party E: $AZN AstraZeneca ($258b mcap) I uploaded all the bidding details to both GPT and Grok requesting best guesses for each party. Then I asked Grok to review GPTs guesses against its guesses and then arrive at a final table; same for GPT of Groks guesses. Here are the final tables GPT then Grok with the following comments: GPT: Groks framework is quite credible especially for Party E = AstraZeneca and Party B = Roche which align with both transaction logic and historical behaviors. The main divergence is Party A where the Novartis link is just too strong to ignore and Party D where CSL"
X Link @3in5saved 2025-10-22T04:03Z XXX followers, XXX engagements

"@BioTechTraderSD What of the fundamentals though as to truth. What do you think about the role of neutrophils in disease severity of HS and the associated significance of C5a-C5aR1 signaling"
X Link @3in5saved 2025-10-22T15:36Z XXX followers, XXX engagements